你还在谈论出口"新三样"吗？中国经济的新"新三样"已经来了！最近大家有没有注意到，A股流传起 了"纪联海""易中天"这样的代码暗语，北交所机器人概念股年内翻倍，恒瑞医药市值逼近5000亿……这 些看似分散的市场热点，背后其实串联着一条清晰的主线。 在近期的一次重要发布会上，证监会主席吴清透露了一个关键信号：A股科技板块市值占比已经突破 1/4，超越了金融和地产的总和！ 但热潮之下，中国的新"新三样"到底处于什么位置？答案是：整体正从"并跑"向"领跑"迈进。 机器人进展最快，已进入全球第一梯队。产业链完整，市场全球最大，零部件国产化不断突破，但高端 伺服电机等核心零部件仍然需要进口。 这信号再明显不过了：机器人、人工智能和创新药正接过经济增长的接力棒，成为中国经济高质量发展 的新"新三样"！今天，我们就来聊聊，这场关乎国运的产业跃迁背后，究竟藏着怎样的逻辑与机遇。 我们先回答一个核心问题：新"新三样"为什么是它们？为什么是现在？ 这得从国内国际两个大局来看。国际上，现在科技就是最硬的拳头。机器人是智能制造的根基，AI是 千行百业的"智慧大脑"，创新药则是生命科学的价值高地——这三者，是任何强国都要争的战略要地。 ...

Group 1 - The medical innovation ETF (516820.SH) experienced a strong increase of 0.98%, with constituent stocks such as BaiLi Tianheng (688506) rising by 3.87%, HengRui Medicine (600276) by 3.38%, and XinChuang (300832) by 2.87% [1] - HengRui Medicine has reached an agreement with Glenmark Specialty, granting Glenmark exclusive rights to develop and commercialize the drug Rukang Trastuzumab in all global regions except for China, Hong Kong, Macau, Taiwan, the USA, Canada, and Europe [1] - The innovative drug sector is expected to maintain its favorable outlook, with continuous policy support and enhanced global competitiveness for Chinese innovative drugs, leading to sustained commercial profitability [1] Group 2 - Institutions remain confident in high-quality innovation and the innovation industry chain, viewing any short-term disturbances as buying opportunities, especially with the anticipated increase in US interest rates which will enhance global liquidity and the trend of technology stocks [2] - Investors who missed the initial rally in the pharmaceutical sector can consider the medical innovation ETF (516820) as a means to capitalize on the rebound of core pharmaceutical assets [2]

你还在谈论出口"新三样"吗？中国经济的新"新三样"已经来了！最近大家有没有注意到，A股 流传起了"纪联海""易中天"这样的代码暗语，北交所机器人概念股年内翻倍，恒瑞医药市值逼 近5000亿……这些看似分散的市场热点，背后其实串联着一条清晰的主线。 在近期的一次重要发布会上，证监会主席吴清透露了一个关键信号：A股科技板块市值占比已 经突破1/4，超越了金融和地产的总和！ 这信号再明显不过了： 机器人、人工智能和创新药正接过经济增长的接力棒，成为中国经济 高质量发展的新"新三样" ！今天，我们就来聊聊，这场关乎国运的产业跃迁背后，究竟藏着 怎样的逻辑与机遇。 我们先回答一个核心问题：新"新三样"为什么是它们？为什么是现在？ 机器人领域，特别是人形机器人，被很多人看作是继电脑、手机、新能源车之后，下一个可能 改变世界的智能终端。A股龙头汇川技术市值超2000亿，三协电机首日涨幅惊人地超过 785%，宇树科技、智元机器人这些还没上市的"潜力股"也成为了资本追逐的"香饽饽"。 AI更不用说了，市值千亿以上的公司已有好几家，"纪联海"，寒武纪、工业富联、海光信息， 搞的是AI算力芯片和基础设施这块的硬骨头，今年上半年订单 ...

Group 1: Market Performance - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index increased by 0.22% as of September 25, 2025, with notable gains from companies such as Jingwei Hengrun (up 6.46%) and Rongchang Bio (up 5.76%) [3] - The Sci-Tech 100 Index ETF (588030) also rose by 0.22%, with a latest price of 1.4 yuan, and has seen a cumulative increase of 2.73% over the past week [3] Group 2: AI Infrastructure Investment - Alibaba's CEO announced at the 2025 Alibaba Cloud Conference that the company is actively advancing a 380 billion yuan AI infrastructure project and plans to invest even more [4] - OpenAI, Oracle, and SoftBank revealed plans to build five new AI data centers in the U.S. under the "Gateway to the Stars" initiative, with total investments expected to exceed 400 billion dollars over the next three years [4] Group 3: Pharmaceutical Developments - Heng Rui Medicine announced a licensing agreement for its innovative drug SHR-A1811 with Glenmark Specialty S.A., receiving an upfront payment of 18 million dollars and potential milestone payments up to 1.093 billion dollars [4] Group 4: ETF Insights - The Sci-Tech 100 Index ETF has shown significant growth, with a recent increase of 385 million yuan in scale, ranking second among comparable funds [6] - The ETF's recent net inflow was 4.1263 million yuan, with a total of 183 million yuan net inflow over the last five trading days [6] Group 5: Sector Composition - The top three sectors in the Sci-Tech 100 Index are Electronics (37.51%), Pharmaceutical Biology (18.97%), and Power Equipment (12.8%), highlighting a strong focus on technology [6][7] - The top ten weighted stocks in the index account for 23.82% of the total index, indicating concentrated investment in key players [7]

恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，公司SHR7280片的药品上 市许可申请获国家药监局受理。SHR7280片是一种口服小分子GnRH受体拮抗剂，可以阻断内源性 GnRH与GnRH受体的结合，抑制LH等促性腺激素的合成和释放，用于辅助生殖技术的控制性超促排卵 治疗。国内外辅助生殖领域尚无口服GnRH拮抗剂获批上市。 ...

（文章来源：每日经济新闻） 每经AI快讯，9月25日，港股恒瑞医药(01276.HK)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交 额4737.84万港元。 ...

公开资料显示，Glenmark Specialty隶属于Glenmark Pharmaceuticals公司，后者是一家以研究为主导的全 球制药公司，总部位于印度孟买，于印度国家证券交易所以及孟买证券交易所上市，业务涵盖创新药、 仿制药及OTC领域，重点关注呼吸、皮肤及肿瘤学治疗领域。在四大洲拥有11家世界级生产设施，业务 覆盖80多个国家，2023年制药销售额位列生物制药公司前100名。 消息面上，恒瑞医药发布公告称，将公司具有自主知识产权的1类创新药瑞康曲妥珠单抗(SHR-A1811) 项目有偿许可给Glenmark Specialty。Glenmark Specialty将向恒瑞支付1800万美元首付款。恒瑞有资格获 得与注册和销售相关的里程碑付款，最高可达10.93亿美元。根据瑞康曲妥珠单抗在授权范围内的销售 情况，Glenmark Specialty将向恒瑞支付相应的销售提成。 恒瑞医药（600276）(01276)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交额4737.84万港元。 ...

公开资料显示，Glenmark Specialty隶属于Glenmark Pharmaceuticals公司，后者是一家以研究为主导的全 球制药公司，总部位于印度孟买，于印度国家证券交易所以及孟买证券交易所上市，业务涵盖创新药、 仿制药及OTC领域，重点关注呼吸、皮肤及肿瘤学治疗领域。在四大洲拥有11家世界级生产设施，业务 覆盖80多个国家，2023年制药销售额位列生物制药公司前100名。 消息面上，恒瑞医药发布公告称，将公司具有自主知识产权的1类创新药瑞康曲妥珠单抗(SHR-A1811) 项目有偿许可给Glenmark Specialty。Glenmark Specialty将向恒瑞支付1800万美元首付款。恒瑞有资格获 得与注册和销售相关的里程碑付款，最高可达10.93亿美元。根据瑞康曲妥珠单抗在授权范围内的销售 情况，Glenmark Specialty将向恒瑞支付相应的销售提成。 智通财经APP获悉，恒瑞医药(01276)早盘涨超4%，截至发稿，涨4%，报90.95港元，成交额4737.84万 港元。 ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]

Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]